<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080764</url>
  </required_header>
  <id_info>
    <org_study_id>ALA-ACV-CT014</org_study_id>
    <nct_id>NCT05080764</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults</brief_title>
  <official_title>A Randomized, Double Blind, Vehicle-controlled, Multicenter Phase II Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris in Adults With Photodynamic Therapy (PDT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biofrontera Bioscience GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biofrontera Bioscience GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for&#xD;
      the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the&#xD;
      respective placebo treatment for moderate to severe Acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in the number of inflammatory lesions (absolute change from baseline) 8 weeks after the last PDT as assessed by investigator.</measure>
    <time_frame>8 weeks after the last PDT</time_frame>
    <description>Outcome 1 is the absolute change in the number of inflammatory lesions at the final visit with respect to baseline as assessed by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment success defined by a minimum improvement of the modified investigator global assessment (mIGA) score by at least 2 assessed 8 weeks after the last PDT and resulting at an mIGA score of 0 (clear) or 1 (almost clear).</measure>
    <time_frame>8 weeks after the last PDT</time_frame>
    <description>Treatment success is defined as a minimum improvement of the mIGA score by at least 2 and resulting at an mIGA score of 0 (clear) or 1 (almost clear).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change in the number of inflammatory lesions (percentage change from baseline) 8 weeks after the last PDT as assessed by investigator.</measure>
    <time_frame>8 weeks after the last PDT</time_frame>
    <description>Outcome 3 is the percentage change of inflammatory lesions from baseline as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in the number of inflammatory lesions (percentage change from baseline) 8 weeks after the last PDT as assessed by the Canfield algorithm.</measure>
    <time_frame>8 weeks after the last PDT</time_frame>
    <description>Outcome 4 is the percentage change of inflammatory lesions from baseline as assessed by an automated lesions count based on pictures taken by Canfields Visia-CR system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of inflammatory and/or non-inflammatory lesions (absolute change and/or percentage change from baseline) as assessed by investigator.</measure>
    <time_frame>4 or 8 weeks after the last PDT</time_frame>
    <description>In particular, the following will be assessed:&#xD;
Inflammatory lesions - 4 weeks after the last PDT&#xD;
Non-inflammatory lesions - 4 weeks after the last PDT&#xD;
Non-inflammatory lesions - 8 weeks after the last PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 4 weeks after the last PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 8 weeks after the last PDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of inflammatory and/or non-inflammatory lesions (absolute change and/or percentage change from baseline) as assessed by the Canfield algorithm</measure>
    <time_frame>8 weeks after the last PDT</time_frame>
    <description>In particular, the following will be assessed:&#xD;
Inflammatory lesions - 8 weeks after the last PDT&#xD;
Non-inflammatory lesions - 8 weeks after the last PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 8 weeks after the last PDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of inflammatory and/or non-inflammatory lesions for subjects with no remaining inflammatory lesions (subjects receiving only 1 PDT; absolute change and percentage change from baseline) as assessed by investigator.</measure>
    <time_frame>4 or 8 weeks after the 1st PDT</time_frame>
    <description>In particular, the following will be assessed:&#xD;
Inflammatory lesions - 4 weeks after the 1st PDT&#xD;
Inflammatory lesions - 8 weeks after the 1st PDT&#xD;
Non-Inflammatory lesions - 4 weeks after the 1st PDT&#xD;
Non-Inflammatory lesions - 8 weeks after the 1st PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 4 weeks after the 1st PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 8 weeks after the 1st PDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of inflammatory and/or non-inflammatory lesions for subjects with no remaining inflammatory lesions (subjects receiving 2 PDTs; absolute change and percentage change from baseline) as assessed by investigator.</measure>
    <time_frame>4 or 8 weeks after the 2nd PDT</time_frame>
    <description>In particular, the following will be assessed:&#xD;
Inflammatory lesions - 4 weeks after the 2nd PDT&#xD;
Inflammatory lesions - 8 weeks after the 2nd PDT&#xD;
Non-Inflammatory lesions - 4 weeks after the 2nd PDT&#xD;
Non-Inflammatory lesions - 8 weeks after the 2nd PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 4 weeks after the 2nd PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 8 weeks after the 2nd PDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of inflammatory and/or non-inflammatory lesions for subjects with no remaining inflammatory lesions (subjects receiving 3 PDTs; absolute change and percentage change from baseline) as assessed by investigator.</measure>
    <time_frame>4 or 8 weeks after the 3rd PDT</time_frame>
    <description>In particular, the following be assessed:&#xD;
Inflammatory lesions - 4 weeks after the 3rd PDT&#xD;
Inflammatory lesions - 8 weeks after the 3rd PDT&#xD;
Non-Inflammatory lesions - 4 weeks after the 3rd PDT&#xD;
Non-Inflammatory lesions - 8 weeks after the 3rd PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 4 weeks after the 3rd PDT&#xD;
Inflammatory &amp; non-inflammatory lesions - 8 weeks after the 3rd PDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success defined by a minimum improvement of the PAS and mPAS equivalent to an improvement of IGA and mIGA by at least 2, assessed by the Canfield algorithm</measure>
    <time_frame>8 weeks after the last PDT</time_frame>
    <description>In particular, the following will be assessed:&#xD;
a. Across all subjects, irrespective of the final parametric acne score (PAS) and modified PAS (mPAS)&#xD;
PAS/mPAS are equivalent to the IGA/mIGA but results from the automated assessment of acne severity based on pictured taken with the canfield system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of scar severity and overall esthetic appearance.</measure>
    <time_frame>8 weeks after last PDT</time_frame>
    <description>As assessed by the investigator via a physical global scale for acne scars (PGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of texture as assessed by Canfield algorithm.</measure>
    <time_frame>8 weeks after last PDT</time_frame>
    <description>Based on pictures taken during the study visits. Pictures will be analyzed with respect to areas of facial roughness and raised topography of acne lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction regarding esthetic outcome and treatment.</measure>
    <time_frame>8 weeks after the last PDT.</time_frame>
    <description>As reported by the subject.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency and severity of adverse events (AEs), serious AEs (SAEs), and treatment-emergent adverse events (TEAEs). TEAE are defined as all AEs with onset or worsening after first treatment with IMP up to the last visit of the subject.</measure>
    <time_frame>from screening to study completion, over a duration of up to approximately 25 weeks</time_frame>
    <description>TEAEs are defined as all AEs with onset or worsening after first treatment with IMP up to the last visit of the subject (approximately 8 weeks post last PDT).</description>
  </other_outcome>
  <other_outcome>
    <measure>Application site skin reactions assessed by the investigator.</measure>
    <time_frame>from screening to study completion, over a duration of up to approximately 25 weeks</time_frame>
    <description>Application site skin reaction categories: discharge, erosion, erythema, exfoliation, fissure, induration, oedema, scabbing, skin flaking, ulceration, vesicles, other; severity of AE: mild, moderate or severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Application site discomfort reported by the subjects.</measure>
    <time_frame>from screening to study completion, over a duration of up to approximately 25 weeks</time_frame>
    <description>pplication site discomfort categories: burning, hyperaesthesia, pain, paraesthesia, pruritus, stinging, warmth, other; severity of AE: mild, moderate or severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain during illumination reported by the subject.</measure>
    <time_frame>from screening to study completion, over a duration of up to approximately 25 weeks</time_frame>
    <description>Assessed by the subjects using an 11-point numeric rating scale, where a score of 0 means &quot;no pain&quot; and a score of 10 means &quot;worst imaginable pain&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in blood pressure</measure>
    <time_frame>at all clinic visits conducted over a duration of approximately 25 weeks</time_frame>
    <description>systolic &amp; diastolic [mmHg]</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in heart rate</measure>
    <time_frame>at all clinic visits conducted over a duration of approximately 25 weeks</time_frame>
    <description>[bpm]</description>
  </other_outcome>
  <other_outcome>
    <measure>changes body temperature</measure>
    <time_frame>at all clinic visits conducted over a duration of approximately 25 weeks</time_frame>
    <description>[°C]</description>
  </other_outcome>
  <other_outcome>
    <measure>investigation of clinical chemistry parameters</measure>
    <time_frame>first and last visit conducted up to approximately 25 weeks apart</time_frame>
    <description>Findings which differ from reference range and are considered to be clinically significant are to be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>investigation of hematology parameters</measure>
    <time_frame>first and last visit conducted up to approximately 25 weeks apart</time_frame>
    <description>Findings which differ from reference range and are considered to be clinically significant are to be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigation of urinalysis parameters</measure>
    <time_frame>first and last visit conducted up to approximately 25 weeks apart</time_frame>
    <description>Findings which differ from reference range and are considered to be clinically significant are to be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status</measure>
    <time_frame>first and last visit conducted up to approximately 25 weeks apart</time_frame>
    <description>Abnormal findings, considered to be clinically significant, are to be reported.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1h incubation BF-200 ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3h incubation BF-200 ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1h incubation vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3h incubation vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)</intervention_name>
    <description>Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).&#xD;
Other Names:&#xD;
ALA-PDT, Ameluz®-PDT</description>
    <arm_group_label>1h incubation BF-200 ALA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)</intervention_name>
    <description>Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).</description>
    <arm_group_label>1h incubation vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)</intervention_name>
    <description>Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).&#xD;
Other Names:&#xD;
ALA-PDT, Ameluz®-PDT</description>
    <arm_group_label>3h incubation BF-200 ALA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)</intervention_name>
    <description>Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).</description>
    <arm_group_label>3h incubation vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willingness and ability of the subject to provide informed consent and to sign the&#xD;
             Health Insurance Portability and Accountability Act (HIPAA) form. A study-specific&#xD;
             informed consent and HIPAA form must be obtained in writing prior to starting any&#xD;
             study procedures. Minors under 18 years of age must be accompanied by the parent(s) or&#xD;
             legal guardian(s) at the time of consent signing. The parent(s) or legal guardian(s)&#xD;
             must also provide informed consent/HIPAA for the subject.&#xD;
&#xD;
          2. Subjects with moderate to severe acne on the face (IGA ≥3, PAS ≥0.5).&#xD;
&#xD;
          3. Presence of ≥20 inflammatory and ≥20 non-inflammatory (open and closed comedones) Acne&#xD;
             vulgaris lesions on the face (should be located within not more than 2 illumination&#xD;
             areas) as assessed by investigator. The investigator's lesion count should be&#xD;
             confirmed by the automated lesion count via the Canfield algorithm (cutoff for&#xD;
             Canfield is a number that is at maximum 20% below the investigator's assessment). As&#xD;
             per investigator's assessment, the number of nodules and cysts should not exceed 5% of&#xD;
             all inflammatory lesions.&#xD;
&#xD;
          4. All sexes, ≥16 years of age.&#xD;
&#xD;
          5. Willingness and ability to comply with study procedures, particularly willingness to&#xD;
             receive up to 3 PDTs within 8 to 10 weeks.&#xD;
&#xD;
          6. Subjects with good general health or with clinically stable medical conditions will be&#xD;
             permitted to be included in the study.&#xD;
&#xD;
          7. Willingness to stop topical facial treatments other than medical cleansers (i.e. face&#xD;
             washes etc.) at least 14 days prior to randomization visit (Visit 2, baseline) and&#xD;
             discontinue medical cleansers in the face at least 1 week prior to randomization visit&#xD;
             (Visit 2, baseline) and thereafter until the end of study (use of soap is allowed but&#xD;
             the product used should not be changed during the study).&#xD;
&#xD;
          8. Females of reproductive potential must have a negative serum pregnancy test and must&#xD;
             use an adequate and highly effective or two effective methods of contraception&#xD;
             throughout the study. (If hormonal contraception is used, the same product and dose&#xD;
             should be taken for at least 6 months before the first treatment and throughout the&#xD;
             entire study.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any known history of hypersensitivity to ALA, porphyrins or excipients of BF-200 ALA.&#xD;
&#xD;
          2. History of soy or peanut allergy.&#xD;
&#xD;
          3. Subjects with sunburn or other possible confounding skin conditions (e.g. wounds,&#xD;
             irritations, bleeding or skin infections) within or in close proximity (&lt; 5 cm&#xD;
             distance) to treatment field. (Reassessment of subjects is allowed once if the sunburn&#xD;
             or other confounding skin conditions is/are expected to resolve within the screening&#xD;
             period.&#xD;
&#xD;
             Reassessment can be done on the day of the actual treatment.)&#xD;
&#xD;
          4. Clinical diagnosis of atopic dermatitis and other cutaneous conditions (e.g. lupus&#xD;
             erythematosis), Bowen's disease, BCC, eczema, psoriasis, acne conglobata, acne&#xD;
             fulminans, or secondary acne (steroid-induced acne, perioral dermatitis, acne&#xD;
             rosacea), squamous cell carcinoma, other malignant or benign tumors in the treatment&#xD;
             field.&#xD;
&#xD;
          5. Clinically significant (CS) medical conditions making implementation of the protocol&#xD;
             or interpretation of the study results difficult or impairing subject's safety such&#xD;
             as:&#xD;
&#xD;
               1. Presence of photodermatoses or porphyria&#xD;
&#xD;
               2. Metastatic tumor or tumor with high probability of metastasis&#xD;
&#xD;
               3. Infiltrating skin neoplasia (suspected or known)&#xD;
&#xD;
               4. Unstable cardiovascular disease (New York Heart Association class III, IV)&#xD;
&#xD;
               5. Unstable hematologic (including Myelodysplastic syndrome), hepatic, renal,&#xD;
                  neurologic, or endocrine condition&#xD;
&#xD;
               6. Unstable collagen-vascular condition&#xD;
&#xD;
               7. Unstable gastrointestinal condition&#xD;
&#xD;
               8. Immunosuppressive condition&#xD;
&#xD;
               9. Presence of clinically significant inherited or acquired coagulation defect&#xD;
&#xD;
          6. Beard or other facial hair that might interfere with the study assessments unless&#xD;
             subject agrees to be clean-shaven throughout the entire study period. (Reassessment of&#xD;
             subjects is allowed once if assessment of acne lesions is impaired by facial hair at&#xD;
             screening. Reassessment can be performed on the day of the actual treatment).&#xD;
&#xD;
          7. Facial procedures such as dermabrasion, chemical or laser peels as well as exposure to&#xD;
             UV radiation (other than sunlight) at least 4 weeks prior to randomization visit&#xD;
             (Visit 2, baseline).&#xD;
&#xD;
          8. Presence of strong artificial pigmentation (e.g. tattoos) or any other abnormality&#xD;
             that may impact lesion assessment or light penetration in the treatment field.&#xD;
&#xD;
          9. Suspicion of drug or alcohol abuse.&#xD;
&#xD;
         10. Any topical medication of the skin prior to screening as defined below:&#xD;
&#xD;
               1. Topical treatment with ALA or ALA-esters (e.g. MAL) or an investigational drug&#xD;
                  in- and outside the treatment field within 8 weeks prior to screening.&#xD;
&#xD;
               2. Topical treatment with immunosuppressive, cytostatic or cytotoxic drugsinside the&#xD;
                  treatment field within 8 weeks prior to screening.&#xD;
&#xD;
               3. Topical administration of medication with hypericin or other drugs with&#xD;
                  phototoxic or photoallergic potential inside the treatment field within 4 weeks&#xD;
                  prior to screening. Subjects may, however, be eligible if such medication was&#xD;
                  applied for more than 4 weeks prior to screening visit without evidence of an&#xD;
                  actual phototoxic/photoallergic reaction.&#xD;
&#xD;
         11. Any use of the below specified systemic treatments within the designated periods:&#xD;
&#xD;
               1. Systemic acne therapy (oral antibiotics within 8 weeks or oral isotretinoin&#xD;
                  within 6 months or start with hormonal therapy for acne within 6 months prior to&#xD;
                  Visit 2).&#xD;
&#xD;
               2. Use of cytotoxic or cytostatic drugs within 6 months, or immunosuppressive&#xD;
                  therapies or use of ALA or ALA-esters (e.g. MAL) within 12 weeks, investigational&#xD;
                  drugs or drugs known to have major organ toxicity within 8 weeks, interferon or&#xD;
                  glycocorticosteroids (oral or injectable) within 6 weeks prior to screening.&#xD;
&#xD;
               3. Start of intake of medication with hypericin or systemically acting drugs with&#xD;
                  phototoxic or photoallergic potential within 8 weeks prior to screening.&#xD;
&#xD;
             Subjects may, however, be screened and randomized if such medication wastaken in or&#xD;
             applied for more than 8 weeks prior to screening visit without evidence of an actual&#xD;
             phototoxic/photoallergic reaction.&#xD;
&#xD;
         12. Breast feeding women.&#xD;
&#xD;
         13. Subject unlikely to comply with protocol, e.g. inability to return for visits,&#xD;
             unlikely to complete the study, or inappropriate in the opinion of the investigator.&#xD;
&#xD;
         14. Prior randomization in the study.&#xD;
&#xD;
         15. A member of study site staff or sponsor staff directly involved in the conduct of the&#xD;
             protocol or a close relative thereof.&#xD;
&#xD;
         16. Simultaneous participation in a further clinical study.&#xD;
&#xD;
        Dosing Day exclusion criteria:&#xD;
&#xD;
          1. Febrile or infectious disease within 7 days prior to PDT visits.&#xD;
&#xD;
          2. Subjects with sunburn, wounds, irritations, bleeding or other confounding skin&#xD;
             conditions within illumination areas at PDT visits.&#xD;
&#xD;
          3. Application of topical glycocorticosteroids in- and outside the treatment field within&#xD;
             7 days prior to PDT visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchel P Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Lübbert, Dr</last_name>
    <phone>+4921487632</phone>
    <phone_ext>87</phone_ext>
    <email>m.luebbert@biofrontera.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALA-PDT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

